Lurbinectedin

Introduction Lurbinectedin is an intravenous anticancer drug marketed under the brand name Zepzelca. It belongs to the class of alkylating antineoplastic agents and is mainly used in small cell lung cancer, a highly aggressive neuroendocrine lung cancer that often responds initially to platinum-based chemotherapy but commonly relapses. Lurbinectedin is pharmacologically important because it targets DNA … Read more